Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Revenue (2019 - 2025)

Historic Revenue for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $11.2 million.

  • C4 Therapeutics' Revenue fell 2689.75% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year decrease of 1057.38%. This contributed to the annual value of $35.6 million for FY2024, which is 7143.96% up from last year.
  • As of Q3 2025, C4 Therapeutics' Revenue stood at $11.2 million, which was down 2689.75% from $6.5 million recorded in Q2 2025.
  • C4 Therapeutics' Revenue's 5-year high stood at $20.1 million during Q4 2021, with a 5-year trough of $2.7 million in Q2 2023.
  • Its 5-year average for Revenue is $8.3 million, with a median of $7.4 million in 2021.
  • In the last 5 years, C4 Therapeutics' Revenue crashed by 8578.54% in 2022 and then surged by 35067.57% in 2024.
  • Over the past 5 years, C4 Therapeutics' Revenue (Quarter) stood at $20.1 million in 2021, then plummeted by 85.79% to $2.9 million in 2022, then rose by 14.26% to $3.3 million in 2023, then surged by 58.75% to $5.2 million in 2024, then soared by 116.92% to $11.2 million in 2025.
  • Its Revenue was $11.2 million in Q3 2025, compared to $6.5 million in Q2 2025 and $7.2 million in Q1 2025.